In Vitro and In Vivo Validation of GATA-3 Suppression for Induction of Adipogenesis and Improving Insulin Sensitivity
![Thumbnail](/bitstream/handle/10576/35542/ijms-23-11142%20%281%29.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Date
2022-09-22Author
Al-Jaber, HendMohamed, Nura A.
Govindharajan, Vijay K.
Taha, Samir
John, Jomon
Halim, Sharique
Alser, Maha
Al-Muraikhy, Shamma
Anwardeen, Najeha Rizwana
Agouni, Abdelali
Elhissi, Abdelbary
Al-Naemi, Hamda A.
Al-Mansoori, Layla
Elrayess, Mohamed A.
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Impaired adipogenesis is associated with the development of insulin resistance and an increased risk of type 2 diabetes (T2D). GATA Binding Protein 3 (GATA3) is implicated in impaired adipogenesis and the onset of insulin resistance. Therefore, we hypothesize that inhibition of GATA3 could promote adipogenesis, restore healthy fat distribution, and enhance insulin signaling. Primary human preadipocytes were treated with GATA3 inhibitor (DNAzyme hgd40). Cell proliferation, adipogenic capacity, gene expression, and insulin signaling were measured following well-established protocols. BALB/c mice were treated with DNAzyme hgd40 over a period of 2 weeks. Liposomes loaded with DNAzyme hgd40, pioglitazone (positive), or vehicle (negative) controls were administered subcutaneously every 2 days at the right thigh. At the end of the study, adipose tissues were collected and weighed from the site of injection, the opposite side, and the omental depot. Antioxidant enzyme (superoxide dismutase and catalase) activities were assessed in animals’ sera, and gene expression was measured using well-established protocols. In vitro GATA3 inhibition induced the adipogenesis of primary human preadipocytes and enhanced insulin signaling through the reduced expression of p70S6K. In vivo GATA3 inhibition promoted adipogenesis at the site of injection and reduced MCP-1 expression. GATA3 inhibition also reduced omental tissue size and PPARγ expression. These findings suggest that modulating GATA3 expression offers a potential therapeutic benefit by correcting impaired adipogenesis, promoting healthy fat distribution, improving insulin sensitivity, and potentially lowering the risk of T2D.
Collections
- Biological & Environmental Sciences [871 items ]
- Biomedical Research Center Research [709 items ]
- Laboratory Animal Research Center (Research) [96 items ]
- Pharmacy Research [1234 items ]